文献速递头颈部肿瘤放疗

每周方案对比脉冲式顺铂联合同步根治性放疗治疗头颈部鳞状细胞癌:系统综述与网状Meta分析

Weekly Versus Bolus Cisplatin Concurrent With Definitive Radiation Therapy for Squamous Carcinoma of the Head and Neck: A Systematic Review and Network Meta-Analysis.
PubMed 文献 · Pract Radiat Oncol · 2024-06-17

该系统综述与网状Meta分析纳入5项随机对照试验共1678例非转移性局部晚期头颈部鳞状细胞癌患者,间接比较每周顺铂与每3周脉冲式顺铂联合同步根治性放疗的疗效。两组总生存无统计学差异(HR 0.90,95%CI 0.53-1.52,P=.345),5年总生存绝对差异为+1.2%(95%CI -6.1%-+5.9%),毒性与次要终点定性分析未见明显差异。

要点

  • 每周与脉冲式顺铂同步根治性放疗的总生存无统计学差异(HR 0.90,95%CI 0.53-1.52,P=.345)。
  • Cox模型显示5年总生存绝对差异为+1.2%(95%CI -6.1%-+5.9%,P=.345)。
  • 次要终点与毒性按方案定性分析未见明显差异。

核心结论

  • 西妥昔单抗试验提供的间接数据提示顺铂方案之间的差异是微小的。

研究设计与样本

  • 遵循PRISMA的系统综述,识别比较顺铂与西妥昔单抗联合同步根治性放疗的随机对照试验。
  • 纳入非转移性局部晚期头颈部鳞状细胞癌,排除含原发手术或诱导治疗的试验。
  • 共识别5项随机试验,包括1678例患者。
  • 使用数字化仪从已发表曲线按事件提取生存时间,并与已发表点估计和HR验证。
  • 采用频率框架下随机效应Cox回归比较生存,Cochrane方法评估偏倚风险,分析计划在Open Science Foundation预注册。

主要发现

  • 每周方案与脉冲式方案的总生存无统计学差异(HR 0.90,95%CI 0.53-1.52,P=.345)。
  • Cox模型提示队列平均患者每周与脉冲式方案的5年总生存绝对差异为+1.2%(95%CI -6.1%-+5.9%,P=.345)。
  • 次要终点和毒性按方案定性分析未见明显差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The schedule of cisplatin concurrent with definitive radiation for squamous carcinoma of the head and neck remains controversial. Most institutions deliver either a high-dose "bolus" schedule once every 3 weeks or a low-dose weekly schedule. We compared these 2 schedules via a simplified network meta-analysis with a common comparator. METHODS AND MATERIALS: We performed a PRISMA-concordant systematic review to identify randomized controlled trials comparing cisplatin with cetuximab for nonmetastatic, locoregionally advanced squamous carcinoma of the head and neck treated with definitive radiation. Trials incorporating primary surgery or induction therapy were excluded. Patient survival times were extracted on a per-event basis from the published curves using a digitizer and validated against published point estimates and hazard ratios (HRs). Survival was compared using random effects Cox regression under a frequentist framework. Toxicity and secondary endpoints were analyzed qualitatively. The Cochrane method assessed the risk of bias. The analysis plan was preregistered with the Open Science Foundation. RESULTS: Five randomized trials were identified, including 1678 patients. There was no statistical difference in overall survival between weekly and bolus regimens (HR, 0.90; 95% CI, 0.53-1.52, P = .345). This Cox model suggested that for the average patient in the cohort, the absolute difference in 5-year overall survival between weekly and bolus regimens was +1.2% (95% CI, -6.1%-+5.9%, P = .345). Secondary endpoints and toxicity were not obviously different by regimen, qualitatively. CONCLUSIONS: The cetuximab trials provide indirect data suggesting that the differences between cisplatin schedules are subtle.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Ward MC, Prabhu RS, Atlas JL, et al. Weekly Versus Bolus Cisplatin Concurrent With Definitive Radiation Therapy for Squamous Carcinoma of the Head and Neck: A Systematic Review and Network Meta-Analysis. Pract Radiat Oncol. 2024. PMID: 38888539. doi:10.1016/j.prro.2024.03.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。